Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entinostat - EOC Pharma/Syndax Pharmaceuticals

Next Previous
X
Search
Drug Profile

Entinostat - EOC Pharma/Syndax Pharmaceuticals

Alternative Names: EDP-103; EOC 103; KHK-2375; MS-27-275; MS-275; SND 275; SNDX-275

Latest Information Update: 01 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsui Pharmaceuticals; University of Tokyo
  • Developer EOC Pharma; Syndax Pharmaceuticals
  • Class Aniline compounds; Antineoplastics; Benzamides; Carbamates; Pyridines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered HER2 negative breast cancer
  • Suspended Bladder cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Uveal melanoma

Most Recent Events

  • 26 Sep 2024 Hoffmann-La Roche completes the phase-I/II MORPHEUS HR+BC trial in HER2-negative-breast-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea, USA, Israel (PO) (NCT03280563)
  • 03 Sep 2024 Syndax Pharmaceuticals terminates phase II trial in Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) due to funder halted development of compound in this disease (NCT03552380)
  • 31 May 2024 Updated efficacy and adverse events data from a phase III trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top